Literature DB >> 9951801

Vasculitis-susceptible genes in mice with a deficit in Fas-mediated apoptosis.

M Nose1, M Terada, M Nishihara, J Kamogawa, T Miyazaki, S Mori, M Nishimura, Y Wang, T Kamoto, H Hiai.   

Abstract

Autoimmune diseases show complex pathological manifestations, which frequently involve systemic vasculitis. This complication is understood to be a manifestation of advanced disease, or to represent distinct entities, restricted by genetic and/or environmental factors. An MRL/Mp strain of mice bearing the Fas deletion mutant gene, lpr (MRL/lpr), spontaneously develop systemic vasculitis coincidentally with glomerulonephritis, arthritis and sialoadenitis, but a C3H/HeJ-lpr/lpr (C3H/lpr) strain does not. Thus, this is a suitable model for analyzing the genetic basis of vasculitis in autoimmune diseases. To genetically dissect these complex pathological manifestations, a linkage analysis of each lesion with polymorphic microsatellite markers was performed by using MRL/lpr x (MRL/lpr x C3H/lpr)F1 backcross mice. Vasculitis-susceptible gene loci were mapped on chromosomes 3 and 4, which were not associated with glomerulonephritis, arthritis and sialoadenitis. These results indicate that systemic vasculitis in MRL/lpr mice may be under the control of host genes which are different from those for other autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9951801     DOI: 10.1016/s0167-5273(98)00146-6

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  2 in total

Review 1.  Immunopathogenesis of vasculitis.

Authors:  Raquel Cuchacovich
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

2.  Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.

Authors:  Marta Christensson; Erna Pettersson; Kjell Eneslätt; Birger Christensson; Johan Bratt; Solbritt Rantapää-Dahlqvist; Karl-Gösta Sundqvist
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.